Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Kalvista Pharmaceuticals Inc.
Headquarters: Salisbury, United Kingdom
Website: http://www.kalvista.com
Year Founded: 2011
Status: Public
Industry Sector: HealthTechnology
CEO: Ben Palleiko, MBA
Number Of Employees: 150
Enterprise Value: $214,443,626
PE Ratio: -3.36
Exchange/Ticker 1: NASDAQ:KALV
Exchange/Ticker 2: N/A
Latest Market Cap: $605,370,496
BioCentury | Dec 17, 2024
Management Tracks
Bruce Cozadd to retire as Jazz’s CEO
Plus: James Li named venture partner at Frazier, and updates from Crinetics, NeoPhore, VectorY and more
BioCentury | Mar 8, 2024
Management Tracks
BioNTech’s Sean Marett retiring
Plus: BioMarin names new commercial head, and updates from KalVista, Vast
BioCentury | Feb 17, 2024
Finance
Public equity report: Five follow-ons total $875M+, PIPEs keep flowing
Plus: LianBio begins winding down, promises dividend; BioXcel pulls offering
BioCentury | Feb 14, 2024
Product Development
Clinical report: Data from Gilead, KalVista, Takeda, Synlogic and AN2
What Gilead’s CD47 failure means for the class; KalVista to submit HAE program; Takeda advances narcolepsy therapy; and more
BioCentury | Jul 26, 2023
Management Tracks
New CEOs for Catalyst, FibroGen, Pheon and Tae
Plus: Nicole Sweeny named chief commercial officer of KalVista
BioCentury | Jan 6, 2023
Management Tracks
Singhal to lead development at Biogen as company splits R&D
Plus: Baumal named CMO at Apellis, and updates from Pheast, Sofinnova Partners, GE, Lexeo and more
BioCentury | Oct 17, 2022
Management Tracks
Baranowski becomes CEO at Avalyn
Plus new CMO at Ankyra as Kaufman becomes CEO, and updates from Verge, Zentalis, Aviceda and more
BioCentury | Oct 5, 2022
Deals
Oct. 4 Quick Takes: BMS taps SyntheX for molecular glue pact
Plus Flagship’s Cellarity raises $121M series C and updates for Inhibrx, Autolus, Vir, Ginkgo and more
BioCentury | Jun 28, 2021
Finance
Gene editing stocks rise after Intellia’s readout, while competitors slip
As Intellia gained about $3 billion in market cap Monday on the strength of early signs of efficacy for its CRISPR-based therapy, a broader optimism lifted shares of a handful of other gene editing
BioCentury | May 4, 2021
Management Tracks
Guardant unveils Eagle as CMO; plus Karyopharm, Arix, Eagle, Gemini, Neoleukin, MEI, Krystal, Relay and more
Cancer diagnostics company Guardant Health Inc. (NASDAQ:GH) hired Craig Eagle as CMO. Eagle, who was most recently was VP of medical affairs oncology at Genentech Inc., is a 19-year veteran of
Items per page:
1 - 10 of 18